Citations

Clear

862 citation(s) found for "Habermann, EB".

The association of physical activity before and after lymphoma diagnosis with survival outcomes
Pophali, Priyanka A. , Ip, Andrew , Flowers, Christopher R. , Link, Brian K. , Farooq, Umar , Allmer, Cristine, Cohen, Jonathon B. , Thompson, Carrie A. , Rosenthal, Allison , Witzig, T.E. , Link, Brian K , Farooq, Umar , Pophali, Priyanka , Larson, Melissa C. , Maurer, Matthew J. , Feldman, Andrew L. , Slager, Susan L. , Witzig, Thomas E. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | September 19, 2018 | Volume: 93 | Issue: 12 | Pages: 1543-1550

10.1002/ajh.25288 | PMID 30230581 Get It

AbstractThe impact of physical activity (PA) on lymphoma survival is not known. The association of PA and change in PA with overall (OS), lymphoma‐specific (LSS) and event‐free (EFS) survival was evaluated in a prospective cohort of newly diagnosed lymphoma patients (2002‐2012). We calculated Leisure Score Indexes (mLSI) from the self‐reported usual adult PA (baseline) and at 3‐years post‐diagnosis (FU3), grouping patients by active vs insufficiently active by the American Cancer Society PA guidelines. Associations of PA with survival were assessed using hazard ratios (HRs) and 95% confidence intervals (CI) from Cox models stratified by lymphoma subtype, adjusted for age, sex, baseline BMI, and comorbidity score with change scores further adjusted for baseline PA. Three thousand sixty participants were evaluable at baseline and 1371 at FU3. Active patients had superior survival from baseline [HR (CI): OS 0.82 (0.72‐0.94); LSS 0.74 (0.61‐0.90); EFS 0.92 (0.82‐1.02)] and FU3 [HR (CI): OS 0.64 (0.46‐0.88); LSS 0.32 (0.18‐0.59); EFS 0.82 (0.61‐1.10)] compared to insufficiently active. An increase in mLSI from baseline to FU3 (vs stable mLSI) was associated with superior OS (HR = 0.70, CI 0.49‐1.00) and LSS (HR = 0.49, CI 0.26‐0.94).The continuous change in mLSI at FU3 was significantly associated with OS, LSS and EFS; maintained across subgroups and appeared linear. Higher PA among lymphoma patients at diagnosis and 3 years is significantly associated with OS, LSS, and EFS. Increasing PA after diagnosis is significantly associated with improved OS and LSS supporting an important role for PA in lymphoma survivorship and the need for intervention trials.
Cryptococcus neoformansinfections in patients with lymphoproliferative neoplasms
Dioverti, M. Veronica , Osmon, Douglas R. , Tande, Aaron J. , Dioverti, Maria V, Tande, Aaron , Dioverti, Maria Veronica , Parikh, Sameer A. , Habermann, Thomas M.

Mayo Clinic

Leukemia & Lymphoma | September 7, 2018 | Volume: 60 | Issue: 4 | Pages: 920-926

10.1080/10428194.2018.1508666 | PMID 30188226 Get It

Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).
Abeykoon, Jithma P. , Kumar, Shaji , King, Rebecca L. , Kyle, Robert A. , Hayman, Suzanne R. , Lacy, Martha Q. , Thompson, Carrie A. , Lust, John A., Ansell, Stephen M. , Kapoor, Prashant , Paludo, Jonas , Gertz, Morie A. , Buadi, Francis K. , Habermann, Thomas M. , Dingli, David , Witzig, Thomas E. , Dispenzieri, Angela , Go, Ronald S. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7552-7552

10.1200/jco.2016.34.15_suppl.7552 Get It

Beyond maximum grade: A novel method to assess toxicity over time in clinical trials of targeted therapy in lymphoma.
Thanarajasingam, Gita , Atherton, Pamela J. , Pederson, Levi , Novotny, Paul J. , Sloan, Jeff A. , Grothey, Axel, Kumar, Shaji , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7546-7546

10.1200/jco.2016.34.15_suppl.7546 Get It

Participation in clinical trials to improve outcomes of patients with relapsed lymphoma.
Nowakowski, Grzegorz S. , Ansell, Stephen M. , Macon, William R. , Ristow, Kay M., Inwards, David J. , Johnston, Patrick B. , Klebig, Robin, Micallef, Ivana N. , Markovic, Svetomir, Porrata, Luis F. , Thompson, Carrie A. , Witzig, Thomas E. , Colgan, Joseph P. , Lin, Yi , Markovic, Svetomir N. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7523-7523

10.1200/jco.2016.34.15_suppl.7523 Get It

Breast cancer-related paraneoplastic neurologic disease.
Murphy, Brittany L. , Zalewski, Nicholas L. , Degnim, Amy C. , McKeon, Andrew , Flanagan, Eoin P. , Pittock, Sean J. , Habermann, Elizabeth B.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 11559-11559

10.1200/jco.2017.35.15_suppl.11559 Get It

11559 Background: Paraneoplastic neurologic disease (PND) is an aberrant immune-mediated response against the nervous system triggered by occult malignancy. Given the rarity of this disease, a paucity of data exists describing breast cancer (BC)-related PND; thus, we sought to further examine this specific population of patients. Methods: Using an institution specific clinical search tool, we identified all patients at our institution from 1997-2016 with a diagnosis of BC-related PND, verified by an international expert. Retrospective review was used to record tumor and treatment factors associated with PND and BC. A descriptive analysis was performed of the characteristics associated with BC-related PND. Results: BC-related PND was diagnosed in 58 female patients. Average age at BC diagnosis was 54.0±10.3 years. Most had invasive cancer of Stage II or higher [Stage 0 (10.3%), I (10.3%), II (44.8%), III (13.8%), IV (6.9%), unknown (13.8%)]. Most patients were hormone receptor (HR)+ (63.8%), while 4 (6.9%) were HR-, and 17 (29.3%) were unknown. Of the 34 patients where Her2/neu (Her2) data was available, 7 (20.6%) were Her2+ and 27 (79.4%) were Her2-. The majority (62.1%) had neurological symptoms prior to BC, 5.2% were concurrent, and 32.7% developed PND after initial BC. The interquartile range for time from PND to BC diagnosis was -8.5 to 10.5 months. Of the 58 patients, 29 (50%) had autoantibodies detected: Purkinje Cell Cytoplasmic Autoantibody Type-1 (PCA-1[anti-Yo]) (10), amphiphysin-IgG (n = 9), Anti-Neuronal Nuclear Autoantibody Type-2 (ANNA-2[anti-Ri]) (n = 5), and other (n = 5). The most common syndromes were cerebellar ataxia (n = 14), myelopathy (n = 11), and myopathy (n = 11). Immunotherapy was used for PND in 53 of 58 (91.4%) patients; benefit from immunotherapy was assessed as complete 0 (0%), robust 11 (20.8%), mild to moderate 28 (52.8%), none 9 (17%), and indeterminate 5 (9.4%). Conclusions: BC-related PND is rare, with only 58 cases over 20 years at a large academic institution. Paraneoplastic symptoms often present prior to BC diagnosis and BC characteristics are typical of the general population. Over 75% of patients benefit from immunotherapy. These data may provide helpful information to providers treating this population of patients.
Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma.
Tracy, Sean , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Allmer, Cristine, Macon, William R. , Maurer, Matthew J. , Witzig, Thomas E. , Drake, Matthew T. , Weiner, George J. , Slager, Susan L. , Habermann, Thomas M. , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e19067-e19067

10.1200/jco.2016.34.15_suppl.e19067 Get It

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).
Evens, Andrew M. , Gascoyne, Randy D. , Quon, Andrew , Ansell, Stephen M. , Petrich, Adam M., Chang, Julie , O’Brien, Timothy E., Cheema, P. , Cescon, Terrence P., Sturtz, Keren , Evens, Andrew M , Hong, Fangxin , Habermann, Thomas M. , Advani, Ranjana H. , Witzig, Thomas E. , Wagner, Lynne I. , Kahl, Brad S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7507-7507

10.1200/jco.2016.34.15_suppl.7507 Get It

Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.
Martin, Peter , Thompson, Carrie A. , Lossos, Izidore S. , Allmer, Cristine, Feldman, Andew L., Friedberg, Jonathan W. , Flowers, Christopher R. , Famà, Angelo , Casulo, Carla , Nastoupil, Loretta J. , Link, Brian K. , Kahl, Brad S. , Maurer, Matthew J. , Jaye, David L. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 10042-10042

10.1200/jco.2018.36.15_suppl.10042 Get It

Predictors of disease progression in smoldering Waldenström macroglobulinemia.
Zanwar, Saurabh , Abeykoon, Jithma P. , Ansell, Stephen M. , Kumar, Shaji , Lacy, Martha Q. , Nowakowski, Grzegorz S. , Kourelis, Taxiarchis , Kyle, Robert A. , Kapoor, Prashant , Dispenzieri, Angela , Witzig, Thomas E. , Buadi, Francis K. , Dingli, David , Leung, Nelson , Rajkumar, S. Vincent , Go, Ronald S. , Habermann, Thomas M. , Lin, Yi , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7571-7571

10.1200/jco.2018.36.15_suppl.7571 Get It